AKT1 and prostate cancer: These reports clearly indicate the need to characterize the downstream signaling pathways modulated by Akt in many cancers, not only to unveil the reasons for such discrepancies, but also to help designing ways to pharmacologically modulate Akt activity or target its downstream effectors for prostate cancer therapy.